Geovax Labs (GOVX)
Market Price (2/3/2026): $2.87 | Market Cap: $2.3 MilSector: Health Care | Industry: Biotechnology
Geovax Labs (GOVX)
Market Price (2/3/2026): $2.87Market Cap: $2.3 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -220% | Weak multi-year price returns2Y Excs Rtn is -139%, 3Y Excs Rtn is -171% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -26 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -762% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -43% | Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 19% | Weak revenue growthRev Chg QQuarterly Revenue Change % is null |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 30% | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -724%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -724% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -1118% | ||
| High stock price volatilityVol 12M is 118% | ||
| Key risksGOVX key risks include [1] a high probability of bankruptcy driven by a critically short cash runway and the recent termination of its BARDA government contract, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -220% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -43% |
| Weak multi-year price returns2Y Excs Rtn is -139%, 3Y Excs Rtn is -171% |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 19% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -26 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -762% |
| Weak revenue growthRev Chg QQuarterly Revenue Change % is null |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 30% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -724%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -724% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -1118% |
| High stock price volatilityVol 12M is 118% |
| Key risksGOVX key risks include [1] a high probability of bankruptcy driven by a critically short cash runway and the recent termination of its BARDA government contract, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Geovax Labs (GOVX) stock has lost about 80% since 10/31/2025 because of the following key factors:
1. Reverse Stock Split. GeoVax Labs implemented a 1-for-25 reverse stock split, effective January 9, 2026, to regain compliance with Nasdaq's minimum bid price requirement. While a reverse stock split increases the per-share price, it often signals underlying financial distress and can lead to negative investor sentiment and further devaluation if the company's fundamentals do not improve.
2. Dilutive Public Offering. In December 2025, GeoVax announced a public offering intended to raise approximately $3.2 million in gross proceeds. Such offerings typically lead to dilution of existing shareholders' equity as new shares are issued, which can depress the stock price.
Show more
1. Reverse Stock Split. GeoVax Labs implemented a 1-for-25 reverse stock split, effective January 9, 2026, to regain compliance with Nasdaq's minimum bid price requirement. While a reverse stock split increases the per-share price, it often signals underlying financial distress and can lead to negative investor sentiment and further devaluation if the company's fundamentals do not improve.
2. Dilutive Public Offering. In December 2025, GeoVax announced a public offering intended to raise approximately $3.2 million in gross proceeds. Such offerings typically lead to dilution of existing shareholders' equity as new shares are issued, which can depress the stock price.
Show more
Stock Movement Drivers
Fundamental Drivers
The -80.2% change in GOVX stock from 10/31/2025 to 2/2/2026 was primarily driven by a -52.1% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 2022026 | Change |
|---|---|---|---|
| Stock Price ($) | 14.14 | 2.80 | -80.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 6 | 3 | -45.4% |
| P/S Multiple | 1.4 | 0.7 | -52.1% |
| Shares Outstanding (Mil) | 1 | 1 | -24.3% |
| Cumulative Contribution | -80.2% |
Market Drivers
10/31/2025 to 2/2/2026| Return | Correlation | |
|---|---|---|
| GOVX | -80.2% | |
| Market (SPY) | 2.0% | 20.5% |
| Sector (XLV) | 7.9% | 9.8% |
Fundamental Drivers
The -84.5% change in GOVX stock from 7/31/2025 to 2/2/2026 was primarily driven by a -62.4% change in the company's P/S Multiple.| (LTM values as of) | 7312025 | 2022026 | Change |
|---|---|---|---|
| Stock Price ($) | 18.01 | 2.80 | -84.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 6 | 3 | -45.4% |
| P/S Multiple | 1.8 | 0.7 | -62.4% |
| Shares Outstanding (Mil) | 1 | 1 | -24.3% |
| Cumulative Contribution | -84.5% |
Market Drivers
7/31/2025 to 2/2/2026| Return | Correlation | |
|---|---|---|
| GOVX | -84.5% | |
| Market (SPY) | 10.3% | 22.7% |
| Sector (XLV) | 19.9% | 15.5% |
Fundamental Drivers
The -94.1% change in GOVX stock from 1/31/2025 to 2/2/2026 was primarily driven by a -82.9% change in the company's P/S Multiple.| (LTM values as of) | 1312025 | 2022026 | Change |
|---|---|---|---|
| Stock Price ($) | 47.75 | 2.80 | -94.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3 | 3 | 8.5% |
| P/S Multiple | 4.0 | 0.7 | -82.9% |
| Shares Outstanding (Mil) | 0 | 1 | -68.4% |
| Cumulative Contribution | -94.1% |
Market Drivers
1/31/2025 to 2/2/2026| Return | Correlation | |
|---|---|---|
| GOVX | -94.1% | |
| Market (SPY) | 16.6% | 24.8% |
| Sector (XLV) | 7.4% | 18.4% |
Fundamental Drivers
The -99.1% change in GOVX stock from 1/31/2023 to 2/2/2026 was primarily driven by a -99.1% change in the company's P/S Multiple.| (LTM values as of) | 1312023 | 2022026 | Change |
|---|---|---|---|
| Stock Price ($) | 303.38 | 2.80 | -99.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 3 | 1260.5% |
| P/S Multiple | 77.0 | 0.7 | -99.1% |
| Shares Outstanding (Mil) | 0 | 1 | -92.3% |
| Cumulative Contribution | -99.1% |
Market Drivers
1/31/2023 to 2/2/2026| Return | Correlation | |
|---|---|---|
| GOVX | -99.1% | |
| Market (SPY) | 77.5% | 14.8% |
| Sector (XLV) | 22.2% | 9.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| GOVX Return | 7% | -83% | -43% | -54% | -93% | -35% | -100% |
| Peers Return | 15% | -57% | -56% | 45% | -11% | 19% | -67% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 1% | 85% |
Monthly Win Rates [3] | |||||||
| GOVX Win Rate | 33% | 17% | 33% | 33% | 25% | 0% | |
| Peers Win Rate | 45% | 32% | 30% | 43% | 53% | 40% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| GOVX Max Drawdown | -3% | -85% | -52% | -80% | -94% | -35% | |
| Peers Max Drawdown | -26% | -68% | -64% | -48% | -49% | -3% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: EBS, SIGA, TNXP, MRNA, NVAX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/2/2026 (YTD)
How Low Can It Go
| Event | GOVX | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -96.4% | -25.4% |
| % Gain to Breakeven | 2713.3% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -54.8% | -33.9% |
| % Gain to Breakeven | 121.1% | 51.3% |
| Time to Breakeven | 183 days | 148 days |
| 2018 Correction | ||
| % Loss | -100.0% | -19.8% |
| % Gain to Breakeven | 349900.0% | 24.7% |
| Time to Breakeven | 269 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -65.4% | -56.8% |
| % Gain to Breakeven | 188.9% | 131.3% |
| Time to Breakeven | 72 days | 1,480 days |
Compare to EBS, SIGA, TNXP, MRNA, NVAX
In The Past
Geovax Labs's stock fell -96.4% during the 2022 Inflation Shock from a high on 2/17/2021. A -96.4% loss requires a 2713.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Geovax Labs (GOVX)
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
AI Analysis | Feedback
Here are 1-2 brief analogies for Geovax Labs (GOVX):
- An early-stage **Moderna** or **BioNTech**, focused on developing vaccines and immunotherapies for a diverse range of infectious diseases and cancers.
- A small, specialized vaccine R&D company, similar to a startup **Novavax**, but leveraging its unique viral vector platform.
AI Analysis | Feedback
- GEO-CM04S1 (COVID-19 Vaccine): A next-generation vaccine candidate designed to provide broad and durable protection against COVID-19 and its variants.
- GEO-PRV01 (Monkeypox/Smallpox Vaccine): A vaccine candidate for the prevention of monkeypox and smallpox infections.
- Gedeptin (Oncology Immunotherapy): A gene-directed enzyme prodrug therapy for the treatment of various solid tumors.
- GV-MVA-VLP-GMCSF (Glioblastoma Immunotherapy): An immunotherapy candidate targeting glioblastoma, a severe form of brain cancer.
AI Analysis | Feedback
Geovax Labs (GOVX) is a clinical-stage biotechnology company focused on developing vaccines and immunotherapies against infectious diseases and cancer. As a development-stage company, Geovax does not currently have commercialized products generating widespread sales to individuals or other companies in the traditional sense of product purchases. Instead, its primary sources of revenue come from research grants, contracts, and strategic licensing agreements with other entities.
Considering its business model, Geovax's "major customers" can be interpreted as the organizations that fund its research and development or license its technology, rather than purchasers of finished goods.
Major Funding Bodies and Strategic Partners:
- National Institutes of Health (NIH): The NIH, particularly the National Institute of Allergy and Infectious Diseases (NIAID), has been a significant long-term source of grant funding and contracts for Geovax's research and development programs. The NIH is a U.S. government agency.
- Biomedical Advanced Research and Development Authority (BARDA): BARDA, part of the U.S. Department of Health and Human Services, has provided funding for certain of Geovax's infectious disease programs, supporting advanced research and development. BARDA is a U.S. government agency.
- Providence Therapeutics Holdings Inc.: Geovax has an exclusive license agreement with Providence Therapeutics, a private Canadian biotechnology company. Under this agreement, Providence Therapeutics is developing certain cancer vaccine candidates utilizing Geovax's MVA-VLP vaccine platform. This represents a strategic partnership and potential source of future milestone payments and royalties; as a private company, it does not have a public stock symbol.
Therefore, while not selling finished products, Geovax's key financial and collaborative relationships are primarily with government agencies funding R&D and other biotechnology companies licensing its technology.
AI Analysis | Feedback
David A. Dodd, Chairman, President & CEO
Mr. Dodd was appointed CEO of GeoVax Labs in September 2018 and has served as Chairman since January 2011 and as a Director since March 2010. His executive management experience spans over 40 years in the pharmaceutical and biotechnology industries. Prior to GeoVax, he served as President & CEO at AEterna Zentaris Inc. and Medizone International, Inc. Notably, during his six-year tenure as President, CEO, and Director of Serologicals Corporation, the company's market value increased from $85 million to $1.5 billion, culminating in an all-cash sale to Millipore Corporation in 2006. He also oversaw the sale of Stem Cell Sciences Plc. as non-executive chairman. Mr. Dodd previously served as President, CEO & Director of Solvay Pharmaceuticals, Inc., where the enterprise value grew from $100 million to $2.5 billion over five years. He is also the founder and CEO of RiversEdge BioVentures LLC, an investment and advisory firm.
Mark W. Reynolds, Chief Financial Officer & Corporate Secretary
Mr. Reynolds joined GeoVax in 2006 and currently serves as the Chief Financial Officer and Corporate Secretary. Prior to joining GeoVax, he held CFO positions at HealthWatchSystems, Inc. (a privately held company), Duska Therapeutics, Inc. (a publicly held biotechnology company), and CytRx Corporation (a publicly held biopharmaceutical company) from 1988 to 2002. He began his career as an auditor with Arthur Andersen & Co. Mr. Reynolds is a certified public accountant.
Dr. Mark J. Newman, Chief Scientific Officer
Dr. Newman is the Chief Scientific Officer at GeoVax, serving in a full-time capacity since March 2022, after previously working on a part-time basis. He holds a PhD.
Dr. Kelly T. McKee, Chief Medical Officer
Dr. McKee serves as the Chief Medical Officer for GeoVax. He holds an M.D. and M.P.H. degrees.
Dr. John W. Sharkey, Vice President, Business Development
Dr. Sharkey has been the Vice President of Business Development for GeoVax since 2022, previously serving as part-time Head of Business Development. He led two transformational transactions for the company that advanced it into Phase 2 programs in Covid-19 and Oncology. He founded Cogas Consulting, LLC in 2010, which provides executive management, technical development, regulatory, and business development services to pharma and medical device companies. Earlier, as CEO of Largent Health, LLC, he oversaw the development and launch of several medical devices. He has held senior executive positions at Novartis and Shionogi, contributing to several significant partnering transactions. Dr. Sharkey holds a Ph.D. in Chemistry.
AI Analysis | Feedback
The following are the key risks to the business of GeoVax Labs (GOVX):- Financial Instability and Going Concern: GeoVax Labs faces significant financial challenges, including negative revenue growth, substantial operating and net margins, and ongoing profitability issues. The company has reported declining revenues, with figures dropping to $2.5 million for the first nine months of 2025 from $3.1 million in 2024, partly due to the termination of the BARDA Project NextGen contract. Its net loss increased to $6.3 million for the third quarter of 2025, and the year-to-date net loss stands at $17 million. GeoVax's cash balance was approximately $5.0 million at the end of Q3 2025, providing an estimated cash runway of only about four months based on current burn rates. These indicators, including a low Piotroski F-Score of 3 and an Altman Z-Score of -46.26, suggest a high possibility of bankruptcy within the next two years, with a reported probability of bankruptcy of 51%.
- Clinical Development and Regulatory Approval Risks: As a clinical-stage biotechnology company, GeoVax's business success is inherently dependent on the successful outcomes of its clinical trials and obtaining necessary regulatory approvals for its vaccine and immunotherapy candidates. Delays, failures, or unexpected results in clinical trials can significantly impede the commercialization of products and the generation of revenue. For instance, the start of a Gedeptin trial was pushed back due to manufacturing and cell line issues. While some candidates, like GEO-MVA, have received expedited development guidance allowing them to proceed directly to Phase III immuno-bridging trials, the inherent risks associated with clinical development and regulatory pathways remain.
- Dependence on External Funding and Potential for Dilution: Given its limited cash reserves and ongoing operational losses, GeoVax Labs is highly reliant on securing additional financing to fund its research and development efforts and maintain operations. The necessity for future capital raises introduces a significant risk of further dilution for existing shareholders, particularly in a challenging capital-raising environment for the broader biotech sector. The company has issued new common units with warrants to attract investors, which while intended to provide future growth opportunities, also reflects the need for external capital and the potential for increased share count.
AI Analysis | Feedback
The advancement and potential market dominance of universal influenza vaccines and other infectious disease vaccine candidates developed by larger, well-funded pharmaceutical companies utilizing potentially more efficacious and rapidly adaptable platforms, such as mRNA technology. Companies like Moderna and Pfizer are actively progressing mRNA-based universal flu vaccine candidates through clinical trials, which, if successful, could significantly diminish the market opportunity for Geovax's MVA-based universal flu program and other pipeline candidates leveraging similar technology.
AI Analysis | Feedback
The addressable markets for Geovax Labs' main products and services are estimated as follows:
- GEO-CM04S1 (COVID-19 vaccine): The global COVID-19 vaccine market was valued at US$13.43 billion in 2024 and is projected to reach US$29.98 billion by 2033.
- Gedeptin® (therapy for head and neck cancer): The global head and neck cancer therapeutics market size was estimated at USD 2.27 billion in 2024 and is projected to reach USD 6.25 billion by 2033. The U.S. head and neck cancer therapeutics market was valued at USD 0.83 billion in 2024 and is expected to reach USD 1.91 billion by 2032.
- Preventive vaccines against Mpox: The global monkeypox vaccine market size was valued at USD 99.1 million in 2024 and is expected to reach USD 434.3 million by 2033.
- Preventive vaccines against smallpox: The global smallpox vaccine market size was valued at USD 69.26 million in 2024 and is projected to reach USD 102.73 million by 2032.
- Preventive vaccines against Ebola: The global Ebola vaccine market is projected to reach an estimated $2.5 billion in 2025 and $5.875 billion by 2033.
- Preventive vaccines against Marburg: The global Marburg Hemorrhagic Fever Drug market size is expected to reach approximately USD 100.996 million by the end of 2025 and USD 154.997 million by 2033.
- Preventive vaccines against Malaria: The global malaria vaccines market size was valued at USD 491.90 million in 2024, growing at a CAGR of 12.7% from 2025 to 2034. However, another report estimates the global malaria vaccines market size at USD 620.0 million in 2025 and forecasted to reach around USD 1,432.7 million by 2032.
- Preventive vaccines against Zika virus: The global Zika virus vaccine market is expected to reach an estimated $27.5 billion by 2031. Other estimates place the global market at USD 19.35 billion in 2024, growing to USD 20.43 billion in 2025, and projected to reach around USD 33.37 billion by 2034.
- HIV vaccine: The global HIV vaccine market is anticipated to expand from $521.224 million in 2021 to $1,606.27 million by 2033.
- GEO-CM02 (Pan-Coronavirus Vaccine): Null
- Immunotherapies for multiple solid tumors (general): Null
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for GeoVax Labs (GOVX) over the next 2-3 years:- Advancement and Potential Commercialization of GEO-MVA Smallpox Vaccine: GeoVax is prioritizing the clinical evaluation of its GEO-MVA smallpox vaccine. The European Medicines Agency (EMA) has granted an expedited development path for this vaccine, allowing it to bypass Phase I and II clinical trials and proceed directly to a Phase III immunobridging trial. This accelerated pathway could significantly hasten market authorization and subsequent revenue generation.
- Progress and Potential Commercialization of GEO-CM04S1 COVID-19 Vaccine: The company is actively advancing its GEO-CM04S1 COVID-19 vaccine, with a particular focus on immunocompromised patients. This demographic represents a substantial target market, encompassing over 40 million adults in the U.S. and an estimated 400 million worldwide. Phase II trials are currently underway for this vaccine candidate.
- Development and Potential Commercialization of Gideptin Cancer Therapy: GeoVax is concentrating on its oncology pipeline, specifically the Gideptin cancer therapy. CEO David Dodd has highlighted the significant potential of Gideptin as a novel cancer treatment.
AI Analysis | Feedback
Share Issuance
- In January 2022, GeoVax completed a private placement issuing common stock and warrants for gross proceeds of approximately $10.0 million.
- In March 2025, the company executed a registered direct offering raising approximately $4.5 million in gross proceeds through the sale of common stock and warrants.
- A registered direct offering in September 2025 generated approximately $2.5 million in gross proceeds (net proceeds of about $2.325 million) from the sale of common stock and warrants.
Inbound Investments
- Institutional investors purchased approximately $1.04 million in GeoVax stock transactions over the last 24 months.
- The March and September 2025 registered direct offerings involved healthcare-focused institutional investors.
Capital Expenditures
- Over the last 12 months, capital expenditures for GeoVax Labs amounted to -$20.65K.
- Net proceeds from the September 2025 offering are designated to advance product candidates, including for capital expenditures, research and development, manufacturing, and clinical studies.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Geovax Labs Stock Slides 61% With A 9-Day Losing Spree | 12/20/2025 | |
| Geovax Labs Earnings Notes | 12/16/2025 | |
| Would You Still Hold Geovax Labs Stock If It Fell Another 30%? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 10.20 |
| Mkt Cap | 0.6 |
| Rev LTM | 461 |
| Op Inc LTM | 32 |
| FCF LTM | -51 |
| FCF 3Y Avg | -56 |
| CFO LTM | -50 |
| CFO 3Y Avg | -53 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -4.8% |
| Rev Chg 3Y Avg | -1.6% |
| Rev Chg Q | -33.9% |
| QoQ Delta Rev Chg LTM | -5.9% |
| Op Mgn LTM | -70.7% |
| Op Mgn 3Y Avg | -27.4% |
| QoQ Delta Op Mgn LTM | -27.0% |
| CFO/Rev LTM | -63.4% |
| CFO/Rev 3Y Avg | -45.9% |
| FCF/Rev LTM | -79.2% |
| FCF/Rev 3Y Avg | -50.2% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.6 |
| P/S | 2.1 |
| P/EBIT | 1.8 |
| P/E | 2.0 |
| P/CFO | -1.1 |
| Total Yield | -3.3% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -55.2% |
| D/E | 0.0 |
| Net D/E | -0.4 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 7.4% |
| 3M Rtn | 0.8% |
| 6M Rtn | 16.6% |
| 12M Rtn | 6.0% |
| 3Y Rtn | -49.0% |
| 1M Excs Rtn | 10.1% |
| 3M Excs Rtn | -9.0% |
| 6M Excs Rtn | 8.2% |
| 12M Excs Rtn | -10.4% |
| 3Y Excs Rtn | -121.2% |
Price Behavior
Price Behavior
| Market Price | $2.80 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 02/23/2007 | |
| Distance from 52W High | -94.1% | |
| 50 Days | 200 Days | |
| DMA Price | $6.06 | $15.81 |
| DMA Trend | down | down |
| Distance from DMA | -53.8% | -82.3% |
| 3M | 1YR | |
| Volatility | 126.4% | 118.3% |
| Downside Capture | 799.02 | 415.50 |
| Upside Capture | -204.38 | 66.31 |
| Correlation (SPY) | 19.6% | 24.6% |
GOVX Betas & Captures as of 1/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 3.42 | 2.78 | 2.26 | 2.31 | 1.52 | 1.39 |
| Up Beta | -3.07 | -3.85 | -2.13 | 0.94 | 1.12 | 0.52 |
| Down Beta | 2.87 | 3.16 | 1.94 | 2.81 | 0.93 | 1.32 |
| Up Capture | -6% | -290% | -156% | -54% | 55% | 36% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 5 | 10 | 15 | 47 | 107 | 304 |
| Down Capture | 951% | 762% | 498% | 330% | 171% | 113% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 14 | 30 | 45 | 76 | 135 | 427 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GOVX | |
|---|---|---|---|---|
| GOVX | -94.3% | 118.1% | -1.80 | - |
| Sector ETF (XLV) | 7.1% | 17.2% | 0.24 | 18.4% |
| Equity (SPY) | 16.0% | 19.2% | 0.64 | 24.8% |
| Gold (GLD) | 66.9% | 23.7% | 2.11 | -3.3% |
| Commodities (DBC) | 7.0% | 16.3% | 0.23 | -1.5% |
| Real Estate (VNQ) | 2.9% | 16.5% | -0.00 | 14.8% |
| Bitcoin (BTCUSD) | -19.7% | 39.9% | -0.46 | 23.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GOVX | |
|---|---|---|---|---|
| GOVX | -73.7% | 161.8% | -0.20 | - |
| Sector ETF (XLV) | 7.3% | 14.5% | 0.33 | 11.8% |
| Equity (SPY) | 14.1% | 17.1% | 0.66 | 15.4% |
| Gold (GLD) | 19.9% | 16.6% | 0.97 | 4.7% |
| Commodities (DBC) | 11.4% | 18.9% | 0.49 | 5.3% |
| Real Estate (VNQ) | 4.5% | 18.8% | 0.15 | 11.1% |
| Bitcoin (BTCUSD) | 20.9% | 57.6% | 0.56 | 11.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GOVX | |
|---|---|---|---|---|
| GOVX | -67.3% | 192.5% | -0.16 | - |
| Sector ETF (XLV) | 10.6% | 16.6% | 0.53 | 2.8% |
| Equity (SPY) | 15.9% | 17.9% | 0.76 | 3.4% |
| Gold (GLD) | 15.0% | 15.3% | 0.81 | 6.2% |
| Commodities (DBC) | 8.3% | 17.6% | 0.39 | 1.6% |
| Real Estate (VNQ) | 5.8% | 20.8% | 0.25 | 0.7% |
| Bitcoin (BTCUSD) | 71.1% | 66.4% | 1.10 | 3.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/13/2025 | -3.8% | -14.5% | -38.9% |
| 7/29/2025 | 1.8% | -3.0% | 0.8% |
| 3/28/2025 | -4.5% | -8.1% | -10.0% |
| 11/13/2024 | -3.3% | -3.3% | -13.0% |
| 8/7/2024 | 5.1% | 82.6% | 92.1% |
| 5/15/2024 | 1.2% | 8.7% | -30.2% |
| 3/1/2024 | -7.5% | -16.1% | -24.4% |
| 11/9/2023 | -1.8% | 1.1% | -40.1% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 7 | 7 | 7 |
| # Negative | 12 | 12 | 12 |
| Median Positive | 1.2% | 3.2% | 11.7% |
| Median Negative | -3.6% | -6.0% | -26.3% |
| Max Positive | 5.1% | 82.6% | 92.1% |
| Max Negative | -9.8% | -24.4% | -66.9% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/13/2025 | 10-Q |
| 06/30/2025 | 07/28/2025 | 10-Q |
| 03/31/2025 | 05/01/2025 | 10-Q |
| 12/31/2024 | 03/27/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/14/2024 | 10-Q |
| 12/31/2023 | 02/29/2024 | 10-K |
| 09/30/2023 | 11/08/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 03/23/2023 | 10-K |
| 09/30/2022 | 11/09/2022 | 10-Q |
| 06/30/2022 | 08/03/2022 | 10-Q |
| 03/31/2022 | 04/27/2022 | 10-Q |
| 12/31/2021 | 03/09/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Spencer, John N Jr | Direct | Buy | 10202025 | 0.55 | 10,000 | 5,498 | 11,767 | Form | |
| 2 | McKee, Kelly T Jr | Chief Medical Officer | Direct | Buy | 8082025 | 0.67 | 1,107 | 742 | 2,341 | Form |
| 3 | Spencer, John N Jr | Direct | Buy | 4112025 | 0.98 | 10,000 | 9,800 | 11,174 | Form | |
| 4 | Sharkey, John W | VP, Business Development | Direct | Buy | 4102025 | 0.99 | 6,000 | 5,940 | 6,129 | Form |
| 5 | Dodd, David A | President, CEO | Direct | Buy | 4012025 | 1.08 | 10,000 | 10,800 | 39,594 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.